Selexis SA Announces Launch Of Novel Cell Selection Platform Designed To Help Advance Difficult-To-Express Protein Therapeutics To The Clinic

GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today the launch of a novel selection method to screen and pick cells with optimal expression levels. Selexis developed SUREselect™ to help partners advance difficult-to-express (DTE) proteins to the clinic.

“SUREselect offers our partners an entirely new way for selecting production clones and gives them unique solutions for programs that otherwise would be terminated due to non-clinically and commercially viable production levels. By achieving high titers of the expressed product, SUREselect can also reduce the overall costs of goods.”

The selection of high-producing and stable mammalian cell lines can represent a bottleneck in process development for the production of biopharmaceuticals, particularly for difficult-to-express and cytotoxic proteins. As part of its ongoing commitment to develop expression solutions for challenging proteins, Selexis has developed SUREselect, a novel and patented selection method based on the co-expression of a vitamin B5 transporter in combination with the transfected therapeutic gene(s) and which exploits CHO cell dependency on this vitamin for energy production. SUREselect strengthens the commonly used antibiotic selection and gives growth advantage to cells’ subpopulation with the best-fitted metabolic responses to DTE production.

Using SUREselect, Selexis has been able to increase production levels four-fold for a range of difficult-to-express proteins, including Fc-fusion proteins and cytokines that were cytotoxic to CHO cell lines. This new development of the SUREtechnology Platform™ provides a unique solution for difficult-to-express proteins, which can rescue programs that otherwise would not be viable for clinical development based on production requirements.

“There continues to be a demand for novel methods for the selection of cell lines stably expressing therapeutic proteins at clinical and commercial levels,” said Igor Fisch, PhD, Selexis chairman and chief executive officer. “SUREselect offers our partners an entirely new way for selecting production clones and gives them unique solutions for programs that otherwise would be terminated due to non-clinically and commercially viable production levels. By achieving high titers of the expressed product, SUREselect can also reduce the overall costs of goods.”

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 95 partners worldwide, nearly 80 drug products in clinical manufacturing and two commercial products utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

FOR MORE INFORMATION
- Web			www.selexis.com
- LinkedIn			www.linkedin.com/company/selexis-sa
- Twitter			www.twitter.com/SelexisSA
- Facebook			www.facebook.com/SelexisSA